3471-31-6

Basic information

• Product Name: 5-Methoxyindole-3-acetic acid
• Synonyms: 2-(5-Methoxy-3-indolyl)acetic acid;5-Methoxy-3-indoleacetic acid 98%;5-methoxy-indole-3-aceticaci;5-methoxyindoleaceticacid;RARECHEM AL BO 1466;TIMTEC-BB SBB003497;5-METHOXYINDOLE-3-ACETIC ACID;5-METHOXY-3-INDOLEACETIC ACID
• CAS NO: 3471-31-6
• Molecular Formula: C₁₁H₁₁NO₃
• Molecular Weight: 205.21
• EINECS: 222-438-3
• Product Categories: Indoles and derivatives;Indoline & Oxindole;Heterocyclic Compounds;Indoles;Simple Indoles;Building Blocks;Heterocyclic Building Blocks
• Mol File: 3471-31-6.mol
• Article Data: 13

Chemical Properties

• Melting Point: 145-148 °C (dec.)(lit.)
• Boiling Point: 343.88°C (rough estimate)
• Flash Point: 223.5°C
• Appearance: light yellow to tan/crystalline
• Density: 1.2235 (rough estimate)
• Vapor Pressure: 9.85E-09mmHg at 25°C
• Refractive Index: 1.5130 (estimate)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.52±0.30(Predicted)
• Water Solubility: insoluble
• BRN: 187161
• CAS DataBase Reference: 5-Methoxyindole-3-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxyindole-3-acetic acid(3471-31-6)
• EPA Substance Registry System: 5-Methoxyindole-3-acetic acid(3471-31-6)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 3
• RTECS: NL3660500
• Hazardous Substances Data: 3471-31-6(Hazardous Substances Data)

Usage

Chemical Properties

OFF-WHITE TO SLIGHTLY BEIGE CRYSTALLINE POWDER

Uses

Different sources of media describe the Uses of 3471-31-6 differently. You can refer to the following data:
1. Reactant for preparation of aryloxybenzothiazoles as inhibitors of NO production 1 Reactant for preparation of transcription inhibitors of novel Gli1 as antitumor agents Reactant for preparation of indole derivatives as NR2B/NMDA receptor antagonists 2 Reactant for preparation of indolyl esters and amides related to indomethacin as selective COX-2 inhibitors 3 Reactant for preparation of quinoline salicylic acid series of P-selectin antagonists 4 Reactant for preparation of prostaglandin D2 receptor antagonists.
2. 5-Methoxyindole-3-acetic Acid is a chemical reagent used in the analysis of the physiological properties of auxins.
3. Reactant for preparation of aryloxybenzothiazoles as inhibitors of NO productionReactant for preparation of transcription inhibitors of novel Gli1 as antitumor agentsReactant for preparation of indole derivatives as NR2B/NMDA receptor antagonistsReactant for preparation of indolyl esters and amides related to indomethacin as selective COX-2 inhibitorsReactant for preparation of quinoline salicylic acid series of P-selectin antagonistsReactant for preparation of prostaglandin D2 receptor antagonists

InChI:InChI=1/C11H11NO3/c1-15-8-2-3-10-9(5-8)7(6-12-10)4-11(13)14/h2-3,5-6,12H,4H2,1H3,(H,13,14)/p-1

Upstream product

• 23304-48-5 (5-methoxy-1H-indol-3-yl)acetic acid methyl ester 
• 2426-19-9 (5-methoxy-1H-indol-3-yl)oxoacetyl chloride 
• 858232-58-3 3-(carboxymethyl)-5-methoxy-1H-indole-2-carboxylic acid 
• 14827-68-0 2-(5-methoxy-1H-indol-3-yl)-2-oxoacetic acid 
• 3471-31-6 5-methoxy-1H-indole-3-acetic acid 
• 15478-18-9 (5-hydroxy-1H-indol-3-yl)acetic acid methyl ester 
• 54-16-0 5-Hydroxyindole-3-acetic acid 
• 104-94-9 4-methoxy-aniline 
• 72963-98-5 ethyl 3-(2-ethoxy-2-oxoethyl)-5-methoxy-1H-indole-2-carboxylate 
• 99988-56-4 methyl 2-(5-methoxy-1H-indol-3-yl)-2-oxoacetate 
• 1006-94-6 5-methoxylindole 
• 57000-49-4 (5-methoxy-1H-indol-3-yl)acetic acid ethyl ester 
• 2436-17-1 5-methoxyindole-3-acetonitrile 

Downstream Products

• 55887-55-3 N,O-Bis(trimethylsilyl)-5-methoxyindolyl-3-essigsaeureester 
• 57000-49-4 (5-methoxy-1H-indol-3-yl)acetic acid ethyl ester 
• 185064-27-1 5-methoxy-1-(phenylmethyl)-1H-indole-3-acetic acid phenylmethyl ester 
• 924635-04-1 2-(1-(benzyloxycarbonyl)-5-methoxy-1H-indol-3-yl)acetic acid 
• 1067133-53-2 C₂₄H₂₈O₄N₂ 
• 712-09-4 5-methoxytryptophol 
• 487-93-4 bufotenin 
• 1019-45-0 N,N-dimethyl-5-methoxytryptamine 
• 1161408-26-9 3-(2-(N-methylamino)phenyl)-6-[(5-methoxy-1H-indol-3-yl)methyl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole 
• 1161408-25-8 3-(4-(N,N-dimethylamino)phenyl)-6-[(5-methoxy-1H-indol-3-yl)methyl]-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole 
• 1134099-85-6 1-(4-benzylpiperidin-1-yl)-2-(5-methoxy-1H-indol-3-yl)ethanone 
• 1167437-79-7 2-(5-methoxy-1-(2,2-diphenylvinyl)-1H-indol-3-yl)acetic acid 
• 1173289-35-4 N-(4-hydroxyphenethyl)-2-(5-methoxy-1H-indol-3-yl)acetamide 
• 1383933-32-1 N-benzyl-2-(5-methoxy-1-methyl-1H-indol-3-yl)acetamide 

Relevant articles and documents

Asymmetric Dearomatizing Fluoroamidation of Indole Derivatives with Dianionic Phase-Transfer Catalyst

Asymmetric dearomatizing fluorocyclization of indole derivatives was investigated using a dicarboxylate phase-transfer catalyst. This reaction proceeds under mild reaction conditions to provide fluoropyrroloindoline derivatives in a highly enantioselective manner. Various substitution patterns on the indole ring are well tolerated. To facilitate the reaction and ensure reproducibility, the addition of water is essential, and its possible role is discussed.

A substituted indole -3 - acetic acid synthesis method (by machine translation)

The present invention provides a substituted indole - 3 - acetic acid synthesis method, comprises the following steps: (1) in order to replace the indole as the starting material, with the acylation reagent under the action of catalyst through the tutor - acylation to obtain the 1, 3 - diacetyl substituted indole; (2) intermediate 1, 3 - diacetyl substituted indole does not need refining, directly with the morpholine and sulfur by the Willgerodt - Kindler rearrangement reaction, the inorganic under the catalysis of alkali hydrolysis, acidified to obtain substituted indole - 3 - acetic acid. (by machine translation)

Erythropoietin Expression Promoter

The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.